Sign In
Buy VTRS
$16.39
+0.120 (+0.738%)
At Close: Jul 13, 2026
Is Viatris Stock in Trouble?
10:00am, Thursday, 10'th Mar 2022
The stock crashed after the company reported earnings.
Viatris Inc. (VTRS) CEO Michael Goettler Presents at Raymond James 43rd Annual Institutional Investors Conference (Transcript)
12:13am, Wednesday, 09'th Mar 2022 Seeking Alpha
Why Viatris Stock Dropped 24% in February
09:51pm, Tuesday, 08'th Mar 2022 The Motley Fool
Investors were unimpressed with the company''s middling fourth-quarter earnings report.
Viatris Inc. (VTRS) CEO Michael Goettler Presents at Raymond James 43rd Annual Institutional Investors Conference (Transcript)
07:13pm, Tuesday, 08'th Mar 2022
Viatris Inc. (VTRS) CEO Michael Goettler Presents at Raymond James 43rd Annual Institutional Investors Conference (Transcript)
Why Viatris Stock Dropped 24% in February
04:51pm, Tuesday, 08'th Mar 2022
Investors were unimpressed with the company's middling fourth-quarter earnings report.
United States: Biocon Biologics Ltd. To Acquire Viatris Biosimilars Portfolio - Goodwin Procter LLP
07:32am, Tuesday, 08'th Mar 2022 Mondaq
On Monday, Biocon Biologics Limited (Biocon) announced that it will acquire Viatris'' rights in biosimilars assets for up to $3.3 billion.
Biocon Biologics Ltd. To Acquire Viatris Biosimilars Portfolio
05:09pm, Monday, 07'th Mar 2022 JD Supra
On Monday, Biocon Biologics Limited (Biocon) announced that it will acquire Viatris’ rights in biosimilars assets for up to $3.3 billion. Viatris and Biocon previously partnered to bring SEMGLEE to market in the U.S. SEMGLEE (insulin glargine-yfgn) injection launched last year in the U.S. as the first-ever interchangeable biosimilar approved by the FDA…. By: Goodwin
3 New Reasons to Sell Viatris Stock Right Now
12:15pm, Monday, 07'th Mar 2022 The Motley Fool
Its latest earnings report is full of red flags.
3 New Reasons to Sell Viatris Stock Right Now
07:15am, Monday, 07'th Mar 2022
Its latest earnings report is full of red flags.
VTRS stock stands out amid selloff in generic drugmakers (NASDAQ:VTRS)
05:00pm, Saturday, 05'th Mar 2022 Seeking Alpha
The shares of Viatris (VTRS) and Teva (VTRS) have well underperformed the broader market over the past 12 months. Find out the opportunities.
Is It Time to Buy the S&P 500's 5 Worst-Performing February Stocks?
07:41am, Saturday, 05'th Mar 2022
Before plowing into some well-known names just because they've seen extreme price drops, take a step back and look at the bigger picture.
Want to Be a Contrarian Investor? Buy Viatris Stock Now
04:23pm, Friday, 04'th Mar 2022 The Motley Fool
After the stock''s sharp downturn, there''s a juicy opportunity waiting for daring investors.
Postherpetic Neuralgia - Global Clinical Trials Market Research Report, H2 2021 Edition - ResearchAndMarkets.com
03:01pm, Friday, 04'th Mar 2022 Kwhen FinanceWant to Be a Contrarian Investor? Buy Viatris Stock Now
11:23am, Friday, 04'th Mar 2022
After the stock's sharp downturn, there's a juicy opportunity waiting for daring investors.
Morning Brief: Biocon''s biosimilar blues: Is pharma giant Biocon''s new business acquisition worth the risk?
02:30am, Friday, 04'th Mar 2022 Economic Times India
Biocon’s recent acquisition of its partner Viatris Inc.''s biosimilar business has shocked the investors as the company’s shares fell nearly 12% on the bourses. Host Dia Rekhi along with Biocon Biologics’ Deputy CEO Shreehas Tambe, ET’s Kiran Somvanshi, and ET Prime’s Vikas Dandekar break down the deal means for the company and the investors and whether the $3.3-billion bet is worth the risk? Credits: ET Now
